InVitria's Cellastim Showcased in Nature Article


For Immediate Release
10/6/08

Fort Collins, CO-A study published in the scientific journal Nature examining embryonic stem cell self-renewal, reported that InVitria's (www.InVitria.com) Cellastim (recombinant human serum albumin) was an effective replacement to bovine serum albumin in ES-cell culture.

The article entitled, "The ground state of embryonic stem cell self-renewal," disclosed that researchers used Cellastim as a recombinant albumin in place of animal-derived serum to eliminate contaminants in the cell culture. The Cellastim was a contributing factor in the enhancement of bulk passaging and clonal propagation .

"This study further supports the use of InVitria's Cellastim as an enhancement to cell culture media," said InVitria President Scott Deeter. "Cellastim is the only supplement available that not only improves cell culture performance, but does so while maintaining a defined and animal free media."

About InVitria (www.InVitria.com)
InVitria has developed cell culture ingredients that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, regenerative medicine, life science research and diagnostics industry. Cellastim is used to enhance cell growth and productivity. It is animal component free and has been used as a cell culture ingredient in regenerative medicine, mammalian cell culture media, stem cell media and primary cell media. (See www.Cellastim.com )

For more information about the InVitria line of products, please e-mail This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call 1-800-916-8311.

Ying, Q.L.et al. The ground state of embryonic stem cell self-renewal. Nature 453, 519-524 (May 2008).

 
  • Blog: The Cell Culture Dish

    Cell Culture Media supplement Blog Strategies for Improving Viral Yield in Vaccine Manufacturing

    A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More

  • Latest News

    Invitria Cell Culture Media News InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference

    March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more